RJA
WHWK

Raymond James & Associates’s Whitehawk Therapeutics WHWK Stock Holding History

Raymond James & Associates’s Portfolio WHWK Stock Details WHWK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-800
Closed -$7K – 3755
2019
Q4 		$7K Hold
800
– – ﹤0.01% 3641
2019
Q3 		$8K Hold
800
– – ﹤0.01% 3574
2019
Q2 		$11K Sell
800
-1,267
-61% -$19.2K ﹤0.01% 3584
2019
Q1 		$28K Buy
2,067
+1,267
+158% +$54.5K ﹤0.01% 3514
2018
Q4 		$20K Hold
800
– – ﹤0.01% 3434
2018
Q3 		$37K Buy
+800
New +$44.9K ﹤0.01% 3509

Other funds holding WHWK

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
NRS
Neville Rodie & Shaw New York $1.55B AUM 46.95% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return

Raymond James & Associates's WHWK Position: Q1 2020 in Review

Raymond James & Associates sold out of Whitehawk Therapeutics (WHWK) in Q1 2020, closing a stake of 800 shares — an estimated $7K sold.

Raymond James & Associates first reported a position in WHWK in Q3 2018 and held it in 6 quarters. The position peaked at $37K in Q3 2018. 18 funds tracked by Wall St. Rank hold WHWK as of Q1 2020.

  • Raymond James & Associates reported no remaining Whitehawk Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Raymond James & Associates sold 800 Whitehawk Therapeutics shares in Q1 2020, an estimated $7K.
  • Raymond James & Associates first reported a position in Whitehawk Therapeutics in Q3 2018 and held it in 6 quarters.
  • Raymond James & Associates's Whitehawk Therapeutics position peaked at $37K in Q3 2018.
  • 18 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q1 2020.

Based on Raymond James & Associates's 13F filing for Q1 2020, filed 21 Apr 2020.